Navigation Links
United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Date:4/18/2013

SILVER SPRING, Md., April 18, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2013 financial results before market open on Thursday, April 25, 2013.

United Therapeutics will host a half-hour teleconference on Thursday, April 25, 2013, at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using conference code: 32040188.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.  [uthr-g]

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
2. Entia Receives Notices of Allowance for its Ergothioneine and Genetic Transporter Patents from the United States, Canada, and Israel
3. Seven Outstanding Doctors Receive Honors From The United States & Canadian Academy of Pathology
4. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
5. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
6. United Therapeutics Announces Additional $420 Million Share Repurchase Program
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
9. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
10. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
11. New Approach to Growing Waste to Value Industry in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, ... new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen ... we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and ...
(Date:3/27/2017)... March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), ... for the detection of foodborne pathogens,  today announced that ... Company Spring 2017 Convention on March 29 at 9:50am ET. ... Marquis. About Roka Bioscience ... Roka Bioscience is ...
(Date:3/27/2017)... ATLANTA , March 27, 2017 Cousins Properties ... of the world,s leading biotechnology companies, has signed a 10-year, ... foot Class A office asset located in the Westshore submarket ... "We are thrilled that Amgen has chosen Corporate Center for ... Larry Gellerstedt , president and chief executive officer of ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
Breaking Biology News(10 mins):